Empowered Patient

Optimizing Health System Resources for Patients Needing Acute Care with Niloy Sanyal LeanTaaS
Empowered Patient

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  • Enhancing Detection of Patients Eligible for Clinical Trials with Pierre Pellier CTMA TRANSCRIPT
    on June 21, 2021 by Karen Jagoda

    Pierre Pellier is CEO of CTMA and is driven to provide better access to innovative and potentially life-saving therapies to more patients. The key is to shorten the duration of clinical trials by more quickly and efficiently identifying and recruiting potentially eligible participants. Using the CT-Scout platform on a mobile device, doctors are prompted to ask, during a consultation, a few selected questions to determine whether a particular patient might be eligible for any of the numerous studies running at their site. Removing the need to remember major inclusion and exclusion criteria encourages doctors and investigators to broaden the search and increase recruitment. @CScoutTm #CTMA #clinicaltrials #patientrecruitment CTMA.fr Listen to the podcast here

  • Enhancing Detection of Patients Eligible for Clinical Trials with Pierre Pellier CTMA
    on June 21, 2021 by Karen Jagoda

    Pierre Pellier is CEO of CTMA and is driven to provide better access to innovative and potentially life-saving therapies to more patients. The key is to shorten the duration of clinical trials by more quickly and efficiently identifying and recruiting potentially eligible participants. Using the CT-Scout platform on a mobile device, doctors are prompted to ask, during a consultation, a few selected questions to determine whether a particular patient might be eligible for any of the numerous studies running at their site. Removing the need to remember major inclusion and exclusion criteria encourages doctors and investigators to broaden the search and increase recruitment. @CScoutTm #CTMA #clinicaltrials #patientrecruitment CTMA.fr Download the transcript here

  • Using Skunkworks Approach to Get More Drugs Through the Pipeline with Mike Rea Protodigm TRANSCRIPT
    on June 17, 2021 by Karen Jagoda

    Mike Rea is the Founder and CEO of IDEA Pharma and Founder of Protodigm, created to develop a new way of progressing drug development. With a fundamental understanding of what goes wrong in early-stage pharmaceutical development, Mike is eager to do more diverse opportunity-seeking for assets in early phase trials. The skunkworks model draws decision and data scientists as well as the pharma people to think outside the box. As Mike says "But I think often in drug development, you get the silos, and people are encouraged to play nicely within the silos. The idea of taking a group of loosely structured, enthusiastic people creating an affinity group that focuses on what could you do differently for an asset, doesn't happen and it's quite hard to do within the confines of the organization." @ProtodigmLabs #Protodigm #skunkworks #NextGenCRO #drugdevelopment Protodigm.co Listen to the podcast here

  • Using Skunkworks Approach to Get More Drugs Through the Pipeline with Mike Rea Protodigm
    on June 17, 2021 by Karen Jagoda

    Mike Rea is the Founder and CEO of IDEA Pharma and Founder of Protodigm, created to develop a new way of progressing drug development. With a fundamental understanding of what goes wrong in early-stage pharmaceutical development, Mike is eager to do more diverse opportunity-seeking for assets in early phase trials. The skunkworks model draws decision and data scientists as well as the pharma people to think outside the box. As Mike says "But I think often in drug development, you get the silos and people are encouraged to play nicely within the silos. The idea of taking a group of loosely structured, enthusiastic people creating an affinity group that focuses on what could you do differently for an asset, doesn't happen and it's quite hard to do within the confines of the organization." @ProtodigmLabs #Protodigm #skunkworks #NextGenCRO #drugdevelopment Protodigm.co Download the transcript here

  • Attacking Rare Disease IgA Nephropathy at the Source in the Gut with Renee Agular-Lucander Calliditas Therapeutics TRANSCRIPT
    on June 15, 2021 by Karen Jagoda

    Renee Agular-Lucander is CEO of Calliditas Therapeutics a Sweden-based clinical-stage biopharmaceutical company focused on the rare kidney disease IgA nephropathy. While there is a genetic predisposition for this autoimmune disease, it is still not clear what triggers the condition and there is no current cure. Renee talks about: Lead drug candidate Nefecon which starts at the top of the disease cascade in the ileum part of the small intestine. Delivering this disease-modifying agent directly interrupts and disrupts the beginning of the disease How clinical trial data is showing the value of addressing the gut-renal axis and treating this indication in an organ-specific way Other orphan indications that might benefit from this approach What the FDA priority review of Nefecon potentially means for the 1 in every 4 adults with IgAN who will eventually succumb to kidney failure. @Calliditas1 #IgANephropathy #IgAN #Kidney #KidneyDisease #EndStageRenalDisease #AutoimmuneDisease #Nefecon #RareDisease Calliditas.se/en Listen to the podcast here

Related Post

NEWSLETTER

Sign up for Breaking News, Newsletter, Blog Posts and Special Deals from 1631 Digital and their media/marketing partners.

Subscribers agree to be contacted from 1631 Digital News and/or their media/marketing partners for breaking news alerts, newsletters and special media marketing offers via email, mail and/or texting communication.